Lebrikizumab Meets Phase 3 End Points in Pediatric Atopic Dermatitis - Summary - MDSpire

Lebrikizumab Meets Phase 3 End Points in Pediatric Atopic Dermatitis

In topline results from Lilly’s ADorable-1 trial, pediatric patients aged 6 months to 18 years had higher rates of skin clearance and itch improvement vs placebo, according to a press release from Eli Lilly and Company.

  • By

  • Kerri Miller

  • March 17, 2026

  • 4 min

Share

Objective:

To evaluate the efficacy and safety of lebrikizumab in pediatric patients with moderate-to-severe atopic dermatitis.

Key Findings:
  • 63% of patients on lebrikizumab achieved at least a 75% reduction in EASI score compared to 22% on placebo.
  • 44% of lebrikizumab patients achieved an IGA score of 0 or 1 versus 15% on placebo.
  • 39% of lebrikizumab patients achieved a 90% reduction in EASI score compared to 11% on placebo.
  • 35% of eligible patients aged 6 years and older on lebrikizumab had a clinically meaningful improvement in itch score versus 6% on placebo.
Interpretation:

Lebrikizumab demonstrates significant efficacy in reducing symptoms of atopic dermatitis in pediatric patients, with a safety profile consistent with previous studies.

Limitations:
  • Findings are based on topline data; full analyses are pending.
  • The trial evaluated a 16-week induction period, with ongoing long-term studies.
Conclusion:

Lebrikizumab shows promise as a treatment option for young patients with moderate-to-severe atopic dermatitis, potentially expanding available therapies for this population.

Original Source(s)

Lebrikizumab Meets Phase 3 End Points in Pediatric Atopic Dermatitis

  • by Kerri Miller

  • March 17, 2026

Related Content

Top 10 Evidence-Based Essentials in Dermatology

A structured framework of guidelines, trials, therapies, and tools used in clinical practice

Case Report: Ivarmacitinib in the treatment of refractory primary cutaneous amyloidosis

Vitiligo Gets Long-Missing Definitions for Severity and Relapse

A new international consensus framework standardizes how disease severity and relapse are defined, addressing inconsistencies that have complicated clinical trials and treatment decisions.